Total Payments
$20,015
2024 Payments
$356.30
Companies
32
Transactions
361
Medicare Patients
3,307
Medicare Billing
$674,711
Payment Breakdown by Category
Research$13,112 (65.5%)
Food & Beverage$6,717 (33.6%)
Education$185.61 (0.9%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $13,112 | 2 | 65.5% |
| Food and Beverage | $6,717 | 348 | 33.6% |
| Education | $185.61 | 11 | 0.9% |
Payments by Type
Research
$13,112
2 transactions
General
$6,903
359 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $13,112 | 2 | $0 (2019) |
| E.R. Squibb & Sons, L.L.C. | $1,096 | 51 | $0 (2023) |
| Genentech USA, Inc. | $852.38 | 59 | $0 (2020) |
| Merck Sharp & Dohme LLC | $666.55 | 37 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $664.66 | 37 | $0 (2024) |
| Celgene Corporation | $613.46 | 32 | $0 (2020) |
| Bayer Healthcare Pharmaceuticals Inc. | $419.38 | 17 | $0 (2023) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $284.70 | 16 | $0 (2019) |
| Incyte Corporation | $260.61 | 14 | $0 (2023) |
| Janssen Biotech, Inc. | $253.63 | 10 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $356.30 | 12 | Eisai Inc. ($99.29) |
| 2023 | $560.02 | 20 | Stemline Therapeutics Inc. ($175.24) |
| 2022 | $123.20 | 4 | E.R. Squibb & Sons, L.L.C. ($58.25) |
| 2021 | $45.55 | 4 | E.R. Squibb & Sons, L.L.C. ($33.18) |
| 2020 | $632.23 | 33 | Merck Sharp & Dohme Corporation ($102.74) |
| 2019 | $6,633 | 95 | Eli Lilly and Company ($4,842) |
| 2018 | $9,838 | 89 | Eli Lilly and Company ($8,270) |
| 2017 | $1,827 | 104 | Genentech USA, Inc. ($498.93) |
All Payment Transactions
361 individual payment records from CMS Open Payments — Page 1 of 15
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/13/2024 | Geron Corporation | RYTELO (Drug) | Food and Beverage | In-kind items and services | $29.96 | General |
| Category: MYELODYSPLASTIC SYNDROME | ||||||
| 11/08/2024 | AstraZeneca Pharmaceuticals LP | EPANOVA (Drug) | Food and Beverage | In-kind items and services | $29.96 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 11/01/2024 | ABBVIE INC. | EPKINLY (Drug) | Food and Beverage | In-kind items and services | $27.82 | General |
| Category: ONCOLOGY | ||||||
| 08/02/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $33.64 | General |
| Category: ONCOLOGY | ||||||
| 06/21/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $34.70 | General |
| Category: ONCOLOGY | ||||||
| 05/24/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $24.99 | General |
| Category: Oncology | ||||||
| 05/10/2024 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Food and Beverage | In-kind items and services | $34.99 | General |
| Category: Oncology | ||||||
| 05/03/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $24.34 | General |
| Category: Oncology | ||||||
| 04/19/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Food and Beverage | In-kind items and services | $32.66 | General |
| Category: Oncology | ||||||
| 03/15/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $24.98 | General |
| Category: Oncology | ||||||
| 02/09/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $33.28 | General |
| Category: Oncology | ||||||
| 01/26/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $24.98 | General |
| Category: Oncology | ||||||
| 12/15/2023 | Stemline Therapeutics Inc. | Orserdu (Drug) | Food and Beverage | In-kind items and services | $29.17 | General |
| Category: Oncology | ||||||
| 12/08/2023 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | Cash or cash equivalent | $23.21 | General |
| Category: Oncology | ||||||
| 11/17/2023 | Stemline Therapeutics Inc. | Orserdu (Drug) | Food and Beverage | In-kind items and services | $27.04 | General |
| Category: Oncology | ||||||
| 11/13/2023 | Bayer Healthcare Pharmaceuticals Inc. | Stivarga (Drug), Vitrakvi | Food and Beverage | In-kind items and services | $34.99 | General |
| Category: Oncology | ||||||
| 10/20/2023 | Pharmacyclics LLC, An AbbVie Company | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $29.79 | General |
| Category: ONCOLOGY | ||||||
| 09/22/2023 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Food and Beverage | In-kind items and services | $24.12 | General |
| Category: Oncology | ||||||
| 08/25/2023 | Stemline Therapeutics Inc. | Orserdu (Drug) | Food and Beverage | In-kind items and services | $29.96 | General |
| Category: Oncology | ||||||
| 07/28/2023 | Stemline Therapeutics Inc. | Orserdu (Drug) | Food and Beverage | In-kind items and services | $29.15 | General |
| Category: Oncology | ||||||
| 07/21/2023 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $27.74 | General |
| Category: Hematology/Oncology | ||||||
| 06/23/2023 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | Cash or cash equivalent | $36.45 | General |
| Category: Oncology | ||||||
| 06/02/2023 | Stemline Therapeutics Inc. | Orserdu (Drug) | Food and Beverage | In-kind items and services | $29.96 | General |
| Category: Oncology | ||||||
| 06/02/2023 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $24.98 | General |
| Category: ONCOLOGY | ||||||
| 05/19/2023 | Seagen Inc. | PADCEV (Biological) | Food and Beverage | In-kind items and services | $29.96 | General |
| Category: Oncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ABEMACICLIB COMBINED WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE IN PATIENTS WITH HIGH RISK, NODE POSITIVE, EARLY STAGE, HORMONE RECEPTOR POSITIVE, HUMAN EPIDERMAL RECEPTOR 2 NEGATIVE, BREAST CANCER | Eli Lilly and Company | $13,112 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 24 | 808 | 26,322 | $1.2M | $366,411 |
| 2022 | 25 | 1,035 | 22,316 | $764,624 | $173,000 |
| 2021 | 23 | 846 | 15,134 | $331,043 | $90,391 |
| 2020 | 9 | 618 | 1,237 | $174,135 | $44,909 |
Total Patients
3,307
Total Services
65,009
Medicare Billing
$674,711
Procedure Codes
82
All Medicare Procedures & Services
82 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 12 | 6,200 | $603,260 | $269,669 | 44.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 143 | 281 | $87,953 | $25,760 | 29.3% |
| Q5103 | Injection, infliximab-dyyb, biosimilar, (inflectra), 10 mg | Office | 2023 | 13 | 1,140 | $207,115 | $17,915 | 8.6% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 62 | 162 | $64,800 | $17,495 | 27.0% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 93 | 170 | $36,550 | $8,925 | 24.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 24 | 31 | $13,640 | $4,547 | 33.3% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 71 | 275 | $17,325 | $3,494 | 20.2% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 28 | 61 | $12,078 | $3,273 | 27.1% |
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | Office | 2023 | 12 | 7,140 | $9,848 | $2,698 | 27.4% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 17 | 17 | $6,018 | $1,775 | 29.5% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 17 | 25 | $4,675 | $1,589 | 34.0% |
| 96411 | Administration of additional new drug or substance into vein using push technique | Office | 2023 | 11 | 33 | $5,643 | $1,519 | 26.9% |
| 96366 | Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | Office | 2023 | 39 | 78 | $4,836 | $1,288 | 26.6% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 30 | 103 | $6,901 | $1,194 | 17.3% |
| J1756 | Injection, iron sucrose, 1 mg | Office | 2023 | 23 | 6,900 | $5,451 | $1,090 | 20.0% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 21 | 44 | $3,960 | $1,055 | 26.6% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 20 | 40 | $3,356 | $934.05 | 27.8% |
| J3489 | Injection, zoledronic acid, 1 mg | Office | 2023 | 28 | 142 | $31,862 | $793.24 | 2.5% |
| 96374 | Injection of drug or substance into vein | Office | 2023 | 19 | 20 | $3,100 | $557.64 | 18.0% |
| J2469 | Injection, palonosetron hcl, 25 mcg | Office | 2023 | 24 | 490 | $24,627 | $410.50 | 1.7% |
| J1453 | Injection, fosaprepitant, 1 mg | Office | 2023 | 11 | 2,100 | $8,358 | $262.02 | 3.1% |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | Office | 2023 | 28 | 740 | $463.20 | $72.51 | 15.7% |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | Office | 2023 | 38 | 88 | $242.46 | $71.18 | 29.4% |
| J3490 | Unclassified drugs | Office | 2023 | 24 | 42 | $316.48 | $26.34 | 8.3% |
| Q5119 | Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg | Office | 2022 | 13 | 1,390 | $191,306 | $50,498 | 26.4% |
About Dr. James Rooney, M.D
Dr. James Rooney, M.D is a Hematology & Oncology healthcare provider based in Worcester, Massachusetts. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/26/2006. The National Provider Identifier (NPI) number assigned to this provider is 1215983358.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. James Rooney, M.D has received a total of $20,015 in payments from pharmaceutical and medical device companies, with $356.30 received in 2024. These payments were reported across 361 transactions from 32 companies. The most common payment nature is "" ($13,112).
As a Medicare-enrolled provider, Rooney has provided services to 3,307 Medicare beneficiaries, totaling 65,009 services with total Medicare billing of $674,711. Data is available for 4 years (2020–2023), covering 82 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Worcester, MA
- Active Since 05/26/2006
- Last Updated 06/04/2015
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1215983358
Products in Payments
- OPDIVO (Biological) $861.44
- Perjeta (Biological) $610.80
- KEYTRUDA (Biological) $592.07
- Abraxane (Drug) $331.27
- GILOTRIF (Drug) $284.70
- JAKAFI (Drug) $260.61
- TAGRISSO (Drug) $256.63
- INJECTAFER (Drug) $249.99
- Stivarga (Drug) $198.51
- Revlimid (Drug) $189.30
- Orserdu (Drug) $175.24
- PADCEV (Biological) $145.35
- Lenvima (Drug) $143.34
- FASLODEX (Drug) $130.75
- DARZALEX (Biological) $113.65
- IMFINZI (Drug) $100.10
- LYNPARZA (Drug) $79.57
- Avastin (Biological) $77.04
- VENCLEXTA (Biological) $75.27
- Nexavar (Drug) $74.83
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Worcester
Dr. Tariq Mughal, M.d, M.D
Hematology & Oncology — Payments: $342,612
Hematology & Oncology $342,612
Viola Zhu, Md Phd, MD PHD
Hematology & Oncology — Payments: $270,026
Hematology & Oncology $270,026
Dr. Shyam Patel, M.d., Ph.d, M.D., PH.D
Hematology & Oncology — Payments: $14,978
Hematology & Oncology $14,978
Madhavi Toke, Md, MD
Hematology & Oncology — Payments: $9,823
Hematology & Oncology $9,823
Vijay Kasturi, M.d, M.D
Hematology & Oncology — Payments: $9,810
Hematology & Oncology $9,810
Saleem Khanani, Md, MD
Hematology & Oncology — Payments: $8,623
Hematology & Oncology $8,623